CD44v7/8 is another alternative splicing isoform of CD44 originally discovered as the lymphocyte homing receptor, which exists in a large range of isoforms functioning as a receptor for the glycosaminoglycan hyaluronan via variability in the pattern of glycosylation (both N- and O-linked) and of multiple splice variants. Since CD44v6 participates in a wide variety of bioprocesses such as cell-cell interactions, cell adhesion and migration, it involves in multiple cellular functions like lymphocyte activation, recirculation and homing, hematopoiesis, and especially tumor metastasis. Therefore, CD44v7/8 is regarded as a functional biomarker and therapeutic target for CAR-T cell immunotherapy.
Structure of the human CD44 hyaluronan-binding domain
Diagram created by Creative Biolabs based on data from Acta Crystallographica Section F: Structural Biology Communications 70.9 (2014): 1155-1161
Anti-CD44v7/8 CAR-T Cell Therapy
The studies of preclinical and clinical anti-CD44v7/8 CAR-T cell therapy has not been reported up to now. Therefore, Creative Biolabs helps researchers capture the brighter and prosperous future of anti-CD44v7/8 CAR-T cell therapy.
Animal Models for in vivo Study of anti-CD44v7/8 CAR-T Cell Therapy
Creative Biolabs offers researchers almost all the animal models generated from the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models for a variety of human malignancies.
The various research applications based on animal models of primary cancers
Quantitative imaging in medicine and surgery 5.5 (2015): 708
Furthermore, Creative Biolabs is always passionate about introducing our well-established animal models to in vivo tests of adoptive cell therapy and providing assistance in creating the most clinically relevant animal models with customized requirements. You request, Creative Biolabs offers the best.
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical CD44v7/8 CAT-T cell therapy research.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Creative Biolabs is thrilled to find values in unexpected areas with original heart and innovations to write the CAR-T cell therapy an incredible scientific revolution.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE